Cerus Corp. Announces a Five-Year Tender Award by the Hong Kong Red Cross Blood Transfusion Service for INTERCEPT Blood Systems
July 30 2020 - 8:30AM
Business Wire
Cerus Corporation (Nasdaq:CERS) today announced it has been
awarded a five-year tender by the Hong Kong Red Cross Blood
Transfusion Services (BTS) for INTERCEPT Blood System for
platelets. The Hong Kong Red Cross BTS is the only public
institution providing blood to all hospitals, public and private,
in Hong Kong.
“Following a thorough selection process, we are pleased to be
selected by the Hong Kong Red Cross BTS to supply INTERCEPT Blood
System for platelets,” said Pascal Maillard, Cerus’ vice president
of commercial operations for the Asia Pacific region. “INTERCEPT
for platelets provides a robust, broad-spectrum inactivation,
reducing the risks of transfusion-transmitted infections and
thereby enhancing patient care.”
“This is an important contract for Cerus,” continued Maillard.
“The Hong Kong Red Cross BTS is a member of the influential Asia
Pacific Blood Network (APBN) and a key opinion leader globally.
This tender award presents a unique opportunity to expand the use
of INTERCEPT in Asia-Pacific, a region that represents a
significant market growth opportunity for Cerus.”
The tender award builds upon the prior experience of the Hong
Kong Red Cross BTS with the INTERCEPT Blood System for platelets.
The Hong Kong Red Cross BTS, in collaboration with the Queen Mary
Hospital, conducted a clinical study successfully transfusing
INTERCEPT treated platelet components prepared without leukocyte
reduction, without bacterial screening, and without gamma
irradiation to allogeneic Hematopoietic Stem Cell Transplant (HSCT)
patients (Sim, Tsoi et al. 2019).
“This innovative study conducted by the Hong Kong Red Cross BTS
and Queen Mary Hospital has the potential to change how patients
are supported with platelet transfusions,” said Dr. Laurence
Corash, Cerus’ chief scientific officer. “The study indicated that
INTERCEPT treatment could potentially replace leukocyte filtration,
a common practice to reduce the incidence of febrile transfusion
reactions, alloimmunization, and cytomegalovirus (CMV) infection.
The INTERCEPT platelet system has already demonstrated widespread
replacement of bacterial screening, gamma irradiation, and CMV
serology in the EU and U.S.”
The Hong Kong Red Cross BTS recently completed renovations and
is a state-of-the-art facility that manufactures approximately
40,000 platelet doses per year, a portion of which will be treated
with INTERCEPT.
Sim, J., W. C. Tsoi, et al. (2019). "Transfusion of
pathogen-reduced platelet components without leukoreduction."
Transfusion 59(6):
1953-1961.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Based in Concord, California, our employees are
dedicated to deploying and supplying vital technologies and
pathogen-protected blood components for blood centers, hospitals
and ultimately patients who rely on safe blood. With the INTERCEPT
Blood System, we are focused on protecting patients by delivering
the full complement of reliable products and expertise for
transfusion medicine. Cerus develops and markets the INTERCEPT
Blood System and remains the only company in the blood transfusion
space to earn both CE Mark and FDA approval for pathogen reduction
of both platelet and plasma components. Cerus currently markets and
sells the INTERCEPT Blood System in the United States, Europe, the
Commonwealth of Independent States, the Middle East and selected
countries in other regions around the world. The INTERCEPT Red
Blood Cell system is in clinical development. For more information
about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
Forward Looking Statements
Except for the historical statements contained herein, this
press release contains forward-looking statements concerning Cerus’
belief that the INTERCEPT Blood System has the potential to change
how patients are supported with platelet transfusions and to
potentially replace leukocyte filtration, and other statements that
are not historical facts. Actual results could differ materially
from these forward-looking statements as a result of certain
factors, including, without limitation: risks related to Cerus’
ability to demonstrate to the transfusion medicine community and
other health care constituencies that pathogen reduction and the
INTERCEPT Blood System is safe, effective and economical; the risk
that applicable regulatory authorities and healthcare practitioners
may disagree with Cerus‘ interpretations of the data from its
clinical studies; as well as other risks detailed in Cerus’ filings
with the Securities and Exchange Commission, including Cerus’
Quarterly Report on Form 10-Q for the quarter ended March 31, 2020,
filed with the SEC on May 5, 2020. In addition, to the extent that
the COVID-19 pandemic adversely affects Cerus’ business and
financial results, it may also have the effect of heightening many
of the other risks and uncertainties described above. Cerus
disclaims any obligation or undertaking to update or revise any
forward-looking statements contained in this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200730005316/en/
Tim Lee – Investor Relations Director Cerus Corporation
925-288-6137
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Sep 2023 to Sep 2024